Abstract:Abstract Fibroblast activation protein has emerged as an attractive biomarker for the imaging and therapyof ~90% of human epithelial cancers due to its expression on cancer associated fibroblasts (CAFs), but not on fibroblasts in healthy tissues. Not surprisingly, several small molecules and peptide-based radioligands that target FAP have been introduced into human clinical trials, but preclinical and clinical data suggest that these radioligand therapies suffer from inadequate tumor uptake, short tumor residence times, or unwanted uptake in the healthy tissues. Hence, there remains an unmet need for development of new FAP-targeted radioligands with improved therapeutic properties. For this purpose, we have designed and synthesized a higher affinity and specificity FAP-targetingligand (FAP8) and linked this ligand via a PEG spacer to both a well-known metal chelator (DOTA)and a 4(-iodo)-phenyl butyric acid pharmacokinetic extender to yield the trifunctional conjugate, FAP8-IP-DOTA. Binding affinity and FAP specificity studies reveal that FAP8-IP-DOTA exhibits high affinity and selectivity for FAP (IC50 = 1.6 nM) relative to its ubiquitous homologs’ prolyloligopeptidase (IC50 = 16.5 nM) and dipeptidyl peptidase-IV (IC50 = 865.0 nM). Moreover, 177Luand 111In radiolabeled forms of the conjugate were found to bind a FAP-transduced cell line (HEK-FAP) with a Kd = 3.0 ± 2 nM, and this binding was completely suppressed upon co-incubation with unlabeled conjugate, i.e., further confirming FAP’s specificity. SPECT/CT imaging studies following intravenous injection of 111In labelled FAP8-IP-DOTA into mice expressing HT29, MDA-MB-231, KB or 4T1 tumors then demonstrated high tumor uptake and remarkably prolonged tumor retention of >8 days. Biodistribution studies of the 177Lu labelledFAP8-IP-DOTA conjugate in mice implanted with either FAP-negative 4T1 tumor cells or FAP-transduced HEK tumor cells at different time points further revealed declining tumor radioactivity from 12.0 to 2.0 % ID/g and 21.0 to 12.0 %ID/g between 1h and 168h post injection, respectively. Importantly, uptake of the same conjugate in the healthy tissues was minimal over this time course, with most radioactivity clearing rapidly. Comparative dosimetry analyses showed tumor: healthy tissues ratios of >5-fold for all major organs. Finally, analysis of tumor inhibiting activity demonstrated that 177Lu-FAP8-IP-DOTA suppressed tumor growth between 60% and 100% in all xenograft models tested (HT29, MDA-MB-231, KB and 4T1), with remarkably improved overall survival rates compared to untreated groups. Based on these promising results, we suggest that FAP8-IP-DOTA warrants further evaluation for possible translation into human clinical trials. Citation Format: Ramesh Mukkamala, Lindemann D. Spencer, Carlson J. Daniel, Pooja Tudi, Miller Nicholas Kaine, Autumn Horner, Srinivasarao Madduri, Philip S. Low. Novel fibroblast activation protein targeting radioligand for imaging and radiotherapy of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1119.

First Experience of Radionuclide Therapy With 177Lu-FAPI-2286 in a Patient With Metastatic Mediastinal Sarcoma

Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice

Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies

68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Recent Clinical Implications of FAPI: Imaging and Therapy

Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy

An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy

Ga68-FAPI Imaging and Lu177-FAPI Therapy in a Case of Metastatic Solitary Fibrous Tumor

Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study

Radioligands Targeting Fibroblast Activation Protein (FAP)

Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT

Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors

Abstract 1119: Novel fibroblast activation protein targeting radioligand for imaging and radiotherapy of solid tumors

68Ga/177Lu-Labeled Theranostic Pair for Targeting Fibroblast Activation Protein with Improved Tumor Uptake and Retention

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

Research Progress for the Clinical Application of Radionuclide Labeling Fibroblast Activation Protein Inhibitor in the Diagnosis and Treatment of Liver Cancer

68Ga-DOTA.SA.FAPi PET in Response Assessment After 177Lu-Microspheres Selective Intra-arterial Radionuclide Therapy for Unresectable Hepatocellular Carcinoma